Aethlon medical publishes preclinical data on the hemopurifier® in transplant immunology journal

Preclinical data suggests expanded therapeutic potential of the hemopurifier® beyond virology and oncology results support further evaluation of the hemopurifier ®  as part of a machine perfusion circuit to further assess its impact on the function of retrieved kidneys san diego , march 10, 2025 /prnewswire/ -- aethlon medical, inc.  (nasdaq: aemd), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases and for use in organ transplantation, today announced the publication of a pre-clinical study in the peer-reviewed journal transplant immunology (https://doi.org/10.1016/j.trim.2025.102215) on february 28, 2025, entitled, " a lectin affinity plasmapheresis device removes extracellular vesicles and micrornas from renal perfusates following controlled oxygenated rewarming of discarded donor kidneys." aethlon medical's hemopurifier® is a therapeutic blood filtration system designed to bind and remove harmful extracellular vesicles and life-threatening viruses from blood and other biological fluids.
AEMD Ratings Summary
AEMD Quant Ranking